In SAFIR02-BREAST IMMUNO study, exploratory analyses identified CD274 gene (encodes the CD274 molecule namely PD-L1) amplification as a potential biomarker of sensitivity to durvalumab (19); however, tumor infiltration lymphocytes (CD8, FoxP3, and CD103) and homologous recombination deficiency did not predict that (19). This evidence concerns the gene CD8A and neoplasm.